MedTrace Logo

MRI Split Scar Sign as a Predictor to Complete Pathologic Response After Neoadjuvant Chemoradiation in Rectal Cancer

NCT04745091 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-02-09

No results posted yet for this study

Summary

Patients with middle or low rectal cancer who receive neoadjuvant chemoradiation and achieve complete clinical response while their pelvic MRI have split scar sign are included. Patients will have total mesorectal excision and pathologic complete response will be assessed

Conditions

  • Rectum Cancer

Interventions

PROCEDURE

total mesorectal excision

excision of the rectum with complete excision of the mesorectum

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Khaled Madbouly, MD, PhD · University of Alexandria

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2021-12-31
Completion
2022-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04745091 on ClinicalTrials.gov